- Home
- TNGX vs GEVO Comparison
TNGX vs GEVO Comparison
Compare TNGX & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | GEVO |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 470.1M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | TNGX | GEVO |
|---|---|---|
| Price | $12.82 | $2.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $13.00 | $6.42 |
| AVG Volume (30 Days) | ★ 3.5M | 2.6M |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $66,501,000.00 | ★ $120,932,000.00 |
| Revenue This Year | $52.80 | $913.54 |
| Revenue Next Year | N/A | $11.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 53.29 | ★ 675.75 |
| 52 Week Low | $1.03 | $0.92 |
| 52 Week High | $13.18 | $2.95 |
Technical Indicators
Market Signals| Indicator | TNGX | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 67.88 | 41.60 |
| Support Level | $11.33 | $1.94 |
| Resistance Level | $13.18 | $2.12 |
| Average True Range (ATR) | 1.08 | 0.08 |
| MACD | 0.34 | -0.00 |
| Stochastic Oscillator | 97.57 | 20.26 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.